News

Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS071 ...
Ever since general relativity pointed to the existence of black holes, the scientific community has been wary of one peculiar ...